timothy sykes logo

Stock News

Is It Too Late to Buy ALLR Stock?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Allarity Therapeutics Inc. is navigating turbulent times as critical reports and developments affect its market performance. Concerns over operational challenges and broader market pressures have significantly impacted investor sentiment. Be mindful, as on Tuesday, Allarity Therapeutics Inc.’s stocks have been trading down by -11.83 percent.

What Recent News Is Shaping ALLR Stock?

Post image

Get my weekly watchlist, free

Sign up to jump start your trading education!

  • The class-action lawsuit around Allarity Therapeutics accuses the company of securities fraud due to misleading statements about its drug Dovitinib and its regulatory status.
  • Shareholders are preparing to sell 18.5M shares, converted from their series A preferred stock, though Allarity won’t receive any proceeds from this sale.
  • Investigations by Wolf Haldenstein and Rosen Law Firm look into allegations of false/misleading statements about FDA meetings and a Wells Notice from the SEC.
  • Another class-action lawsuit alleges misleading investors concerning regulatory prospects and illegal conduct, raising risks of regulatory scrutiny and harm.

Candlestick Chart

Live Update at 15:01:48 EST: On Tuesday, September 17, 2024 Allarity Therapeutics Inc. stock [NASDAQ: ALLR] is trending down by -11.83%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of Allarity Therapeutics’ Recent Earnings Report and Financial Metrics

When we dive into the financial waters of Allarity Therapeutics, the numbers tell quite a complex story. With a recorded sharp drop in stock prices from $3.71 to $2.99 on Sep 17, 2024, it is not the best days for the company.

Revenue numbers and profitability ratios are somewhat grim. The constant loss from operations painted a bleak picture, showing an EBITDA of -$1.63M, net income at a loss of -$1.63M, and operating income at -$3.37M. This implies that the operational aspects aren’t faring too well, digging into the company’s value significantly. Their revenue per share was non-existent which, for many investors, could signal deeper, unresolved financial struggles.

Interestingly, the price-to-book ratio standing at 0.24 indicates that the market values Allarity well below its book value. Essentially, the market is pessimistic about Allarity’s potential to leverage its assets productively. The enterprise value figures were startling too- at a negative $13,133,243, driving home the fragile state the company is currently maintaining.

In other financial highlights, the free cash flow was reported at -$7.22M, leading to a scenario where Allarity must be quenching its cash requirements via issuing stock or acquiring substantial debt. With stock-based compensation recorded at $111K, it’s evident the reliance to lure top talents and keep the workforce stable leans heavily on stock promises.

Moreover, there is a long list of lawsuits filed against Allarity. One can see the investigation into misleading information regarding FDA meetings could cloud investor sentiments further. Lawsuits not only drain financial resources but tarnish a company’s reputation, making it harder to bounce back quickly.

More Breaking News

The Impact of Investigations and Lawsuits on ALLR Stock Value

To put it simply, Allarity is battling several legal storms simultaneously. The class-action lawsuit and investigations from law firms like Rosen Law Firm and Wolf Haldenstein create an overcast ambiance, spreading negativity around its stock. The number of lawsuits piling up sends a loud message to the market — caution is necessary when betting on Allarity.

When I hear “class-action lawsuit”, I mentally picture an old ship caught amidst a ruthless storm, struggling with every wave. Such suits directly translate to heavy legal fees, potential settlements, and a drastic dip in investor trust.

One cannot overlook shareholders dumping over 18.5 million shares either. This underscores a lack of confidence among shareholders, potentially monitoring a fallout due to internal mishandlings. Losing the trust of your shareholders is like losing the lifeline of a business — without that backbone support, crumbling becomes an inevitable path.

Recall how on Aug 30, 2024, after releasing the news regarding shareholder sell-offs, Allarity’s stock price slid down by nearly 1.9% in after-hours trading. Each lawsuit or investigation further stokes the fire, hastening the erosion of trust and value.

Stock Predictions Based on Market Trends and News Sentiment

In conclusion, the rough waters aren’t showing signs of calming anytime soon for Allarity Therapeutics. The financials highlight a sinking ship grappling to stay afloat with numerous leaks — lawsuits and investigations adding to the woes.

With an EBIT margin and profitability remaining elusive concepts for Allarity, one must tread carefully when considering an investment. The market’s skepticism, reflected in the plummeting stock prices and low traded volumes, should serve as flashing warning lights.

As an experienced financial expert, my opinion leans towards a cautious, vigilant approach with Allarity Therapeutics. With ongoing legal hurdles, negative profit margins, and fluctuations in stock prices driven by investor sell-offs, it’s a turbulent ride ahead for potential investors. My advice would be — keep monitoring the developments, wait for signs of stability and improvement before considering plunging into Allarity therapeutics. Patience here, as seen with tempting yet risky penny stocks, could indeed save you from substantial financial heartbreaks.

Remember, markets are not strangers to movements born out of trepidation and excitement. Keep that knowledge as your compass and navigate wisely.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity. Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”